Report of Foreign Issuer (6-k)
20 April 2018 - 6:56AM
Edgar (US Regulatory)
United
States
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the Month of April, 2018
Commission File Number: 001-35892
GW
PHARMACEUTICALS PLC
(Translation of registrant’s name
into English)
Sovereign
House
Vision
Park
Histon
Cambridge
CB24 9BZ
United
Kingdom
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Other Events
On April 19, 2018, GW Pharmaceuticals plc
(“GW” or the “Company”), along with its U.S. subsidiary Greenwich Biosciences, announced that the Peripheral
and Central Nervous System Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) unanimously recommended supporting
the approval of the New Drug Application (NDA) for the investigational cannabidiol oral solution (CBD), also known as Epidiolex®,
for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome in patients two years
of age and older. If approved, Epidiolex would be the first pharmaceutical formulation of purified, plant-based CBD, a cannabinoid
lacking the high associated with marijuana, and the first in a new category of anti-epileptic drugs (AEDs). This public meeting
was presented live through FDA’s website. A copy of the Company’s press release is attached as Exhibit 99.1 hereto
and is incorporated by reference herein. The information contained in Exhibit 99.1 shall not be deemed “filed” for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by
reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, unless expressly set forth by specific
reference in such a filing.
Exhibits
99.1
|
Press Release dated April 19, 2018
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
GW Pharmaceuticals plc
|
|
|
|
|
By:
|
/s/ Douglas B. Snyder
|
|
Name:
|
Douglas B. Snyder
|
|
Title:
|
Chief Legal Officer
|
|
|
|
Date: April 19, 2018
|
|
|